NCT00599820

Brief Summary

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Nov 2005

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2005

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2005

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2006

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 30, 2006

Completed
1.6 years until next milestone

First Posted

Study publicly available on registry

January 24, 2008

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

Enrollment Period

Same day

First QC Date

June 30, 2006

Last Update Submit

May 31, 2024

Conditions

Angioid StreaksChoroidal Neovascularization

Keywords

Angioid StreaksChoroidal NeovascularizationBevacizumab

Outcome Measures

Primary Outcomes (3)

  • BCVA

  • Fluoresceine Angiography

  • Optical Coherence Tomography

Interventions

Intravitreal BevacizumabDRUG

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of Angioid Streaks
  • Choroidal neovascularization associated
  • Untreated patients or patients treated once with PDT

You may not qualify if:

  • Ocular surgery excepting uncomplicated phacoemulsification
  • Glaucoma or any other ocular pathology

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asociación para Evitar la Ceguera en México (APEC)

Mexico City, Mexico City, 04030, Mexico

Location

MeSH Terms

Conditions

Angioid StreaksChoroidal Neovascularization

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesChoroid DiseasesUveal DiseasesNeovascularization, PathologicMetaplasiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Adriana Solís-Vivanco, MD

    Asociación para Evitar la Ceguera en México

    PRINCIPAL INVESTIGATOR

  • Jans Fromow-Guerra, MD PhD

    Asociación para Evitar la Ceguera en México

    STUDY CHAIR

  • Mariana Martínez-Castellanos, MD

    Asociación para Evitar la Ceguera en México

    STUDY CHAIR

  • Elizabeth Reyna-Castelán, MD

    Asociación para Evitar la Ceguera en México

    STUDY CHAIR

  • Myriam Hernández-Rojas, MD

    Asociación para Evitar la Ceguera en México

    STUDY CHAIR

  • Griselda Alvarez-Rivera, MD

    Asociación para Evitar la Ceguera en México

    STUDY CHAIR

  • Hugo Quiroz-Mercado, MD

    Asociación para Evitar la Ceguera en México

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 30, 2006

First Posted

January 24, 2008

Study Start

November 1, 2005

Primary Completion

November 1, 2005

Study Completion

May 1, 2006

Last Updated

June 3, 2024

Record last verified: 2024-05

Locations

ME(1)